Hercules Capital

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Job&Talent is a leading marketplace focused on connecting individuals with employment opportunities through a sophisticated platform. Founded in 2009 and headquartered in Madrid, the company utilizes advanced technology to streamline the hiring process, offering services that include job matching, staff management, staffing, and payroll solutions. This innovative approach enables companies to build agile workforces while providing workers with reliable and flexible job options. In 2022, Job&Talent successfully placed over 340,000 workers in more than 2,500 companies, generating €1.9 billion in revenue. The company operates in ten countries across Europe, the U.S., and Latin America, and has plans for further expansion. With backing from prominent investors, Job&Talent has established itself as the highest-valued unicorn in Spain.

Remodel Health provides innovative employee health benefits solutions. The company offers a software platform that helps employers transition to individual coverage health reimbursement arrangements (ICHRA) to provide more personalized and cost-effective health benefits to their employees. Remodel Health is the expert guide for employers and brokers navigating the complexities of transitioning to ICHRA. They help businesses of all sizes retain more employees by offering individualized health benefits solutions.

Omio is a travel platform founded in 2012 and headquartered in Berlin, Germany. It allows users to compare, plan, and book various modes of travel, including trains, buses, flights, and hotels. The platform features a multi-mode search tool that helps travelers explore different route options by integrating diverse data sources, making it easier to visualize and compare costs and travel times. Omio does not include urban public transport options but focuses on long-distance travel planning. The service aims to provide a simple, flexible, and personalized experience for travel enthusiasts, facilitating real-time price comparisons and bookings based on users' preferred dates and locations.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.

Behavox Ltd. specializes in compliance surveillance software tailored for the capital markets sector. Its offerings include Behavox Compliance, an employee monitoring and risk scoring system, and Behavox Voice, which processes and analyzes voice recordings with multi-lingual capabilities. The company has developed a unified enterprise platform that aggregates various data types into a single data lake, allowing for real-time querying and the application of machine learning to identify misconduct and insider threats. Behavox's innovative approach combines sophisticated engineering with insights from academic research, enabling the continuous improvement of detection algorithms and facilitating the early identification of market abuse, fraud, and other risky behaviors. Founded in 2014, Behavox is headquartered in London, with additional offices in St Petersburg, Russia, and Tokyo, Japan, and operations in Canada.

Smartsheet Inc. is a cloud-based platform designed for effective work execution, enabling organizations to manage projects, programs, and processes with enhanced efficiency. Founded in 2005 and headquartered in Bellevue, Washington, Smartsheet provides a range of collaborative tools tailored to various business needs. Its offerings include Smartdashboards for real-time visibility, Smartportals for easy access to project resources, Smartcards for workflow organization, and Smartgrids for tracking multiple tasks. The platform also features Smartprojects for team collaboration, Smartcalendars for aligning deadlines, Smartforms for structured information collection, and Smartautomation for process automation. Additionally, Smartsheet integrates with existing enterprise applications, facilitating seamless operations across diverse sectors such as aerospace, healthcare, finance, and technology. The company generates revenue through software subscriptions and additional charges for enhanced platform capabilities.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Thumbtack, Inc. operates an online marketplace that connects homeowners with skilled professionals across various service sectors. The platform allows users to find and hire service providers for tasks such as moving, plumbing, electrical work, landscaping, and event management, among others. With a network of around 300,000 local service businesses, Thumbtack offers personalized guidance to homeowners, helping them navigate project timelines and make informed hiring decisions. Established in 2008 and headquartered in San Francisco, California, the company aims to simplify home management by enabling users to efficiently manage home-related tasks and improvements.

Pindrop specializes in providing advanced phone fraud detection and call center authentication technology, aimed at enhancing security and trust in voice interactions. By analyzing call audio, Pindrop's solutions can locate and authenticate phone devices, effectively identifying fraudulent calls and verifying legitimate ones through a comprehensive risk database. This technology enables enterprises to streamline call center operations, reduce call times, and improve customer experiences while minimizing fraud losses. As businesses increasingly rely on voice-driven interactions, Pindrop is committed to unlocking the value of these exchanges, ensuring that both enterprises and consumers can engage securely and confidently.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Semperis, Inc. is an enterprise identity protection company that specializes in safeguarding and recovering Active Directory environments from cyber breaches and identity system failures. Founded in 2013 and headquartered in New York, with an additional location in Ramat Gan, Israel, Semperis provides a suite of solutions, including the Directory Services Protector, which allows organizations to automatically restore an entire Active Directory forest and quickly recover critical attributes. Their offerings also include the Active Directory Forest Recovery and the Active Directory State Manager, which facilitate real-time granular searches, comparisons, and restorations of attributes. Semperis serves a diverse range of industries, including financial services, healthcare, and government, helping clients enhance their cyber resilience and protect against data breaches and operational errors.

Adaptimmune is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, established in 2007. The company specializes in the development of T cell therapies aimed at treating cancer, human immunodeficiency virus, and infectious diseases. Adaptimmune employs a proprietary platform to identify cancer targets, genetically engineer T-cell receptors, and produce therapeutic candidates for patient administration. Its key programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell therapy, and CD70, among others, focusing primarily on solid tumors. By utilizing affinity T cell receptor proteins, Adaptimmune enhances the ability of patient T cells to target and destroy cancerous or infected cells.

Harness, Inc. is a developer of a Continuous Delivery-as-a-Service platform aimed at streamlining the software delivery process for engineering and DevOps teams. Established in 2015 and headquartered in San Francisco, California, Harness leverages machine learning to automate various aspects of code deployment, including verifications, testing prioritization, and impact assessments. The platform features tools such as a pipeline builder, workflow wizard, continuous verification, automated rollback, secrets management, audit trails, and real-time delivery analytics. By facilitating the adoption of cloud initiatives and orchestration tools like Kubernetes and Amazon ECS, Harness helps companies accelerate their deployment processes and improve efficiency in releasing applications into production.

Electric Hydrogen is a company focused on developing low-cost, high-efficiency, fossil-free hydrogen systems aimed at decarbonizing industrial sectors such as ammonia and steel production, which are significant contributors to global greenhouse gas emissions. By rethinking electrolysis, Electric Hydrogen seeks to make clean hydrogen competitive with traditional, fossil-fuel-based hydrogen in terms of cost and scalability. The company's advanced PEM technology utilizes low-cost renewable electricity to produce clean hydrogen gas, thereby helping industries reduce their reliance on fossil fuels and minimize pollution. With a leadership team experienced in transformative clean energy companies, Electric Hydrogen is positioned to address current challenges in efficiency and cost, contributing to the goal of a zero-emission industrial sector in the near future.

SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Reveleer operates a healthcare analytics platform that provides Software-as-a-Service solutions for medical record analysis, enabling health plans to manage risk adjustment and quality improvement programs effectively. The platform facilitates medical record collection, retrieval, and secure printing while offering targeted solutions for Medicare, Medicaid, and commercial sectors, including HEDIS hybrid and supplemental services. Additionally, Reveleer provides extensive support in abstractor training, coding, auditing, and strategic assessments, which evaluate key metrics and operational practices. Founded in 2009 and based in Glendale, California, the company was formerly known as Health Data Vision, Inc. before rebranding in 2019. Reveleer's comprehensive services empower payers to execute and manage provider outreach, coding, abstraction, and reporting independently or collaboratively, enhancing overall accuracy and efficiency in healthcare data management.

Sight Sciences is a medical device company specializing in ophthalmic devices and glaucoma implants aimed at treating irreversible blindness. Headquartered in Menlo Park, California, the company has developed the OMNI Surgical System, which allows for targeted treatment of glaucoma by addressing three points of resistance with a single device and incision. Additionally, Sight Sciences offers TearCare, a wearable technology that delivers adjustable thermal energy to the meibomian glands to treat conditions like dry eye and meibomian gland dysfunction. The company also provides SmartLid, which aids in the natural expression of meibum when it is in a melted state. Founded in 2010, Sight Sciences focuses on both surgical and non-surgical technologies to address prevalent eye diseases and has a commercial office in Southlake, Texas.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Shield AI Inc is a San Diego-based company that specializes in developing artificial intelligence systems for national security and first responders. Founded in 2015, the company creates products that enhance safety for service members and civilians through advanced AI technologies. Its prominent offerings include Nova, an autonomous quadcopter drone equipped with lidar technology, capable of navigating in GPS-denied environments to provide real-time imagery and mapping for military operations. Additionally, the company’s Hivemind software allows various unmanned vehicles, including drones and aircraft, to operate autonomously without GPS or human intervention, thereby maintaining maneuverability in contested settings. Shield AI also incorporates the V-BAT, a vertical takeoff and landing aircraft, which has demonstrated resilience in challenging regions such as the Black Sea and the Middle East. The company aims to transform defense operations through innovative machine learning applications, enabling unmanned systems to perform complex tasks in dynamic and unscripted environments.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company offers a comprehensive digital platform that combines artificial intelligence with human support, providing users access to coaches, nutritionists, diabetes educators, nurses, trainers, and licensed therapists. This platform features personalized content, lessons, and habit recommendations, along with video sessions and messaging to facilitate communication. Vida Health's approach aims to treat the whole health of individuals by integrating mental and physical care, helping users prevent, manage, and potentially reverse chronic conditions such as diabetes and hypertension, as well as associated mental health issues like stress, depression, and anxiety. Founded in 2014, Vida Health has earned the trust of major employers and health plans in the United States for its clinically validated services.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on developing innovative implantable CGM products, including the Eversense and Eversense XL systems, which measure glucose levels for up to 90 and 180 days, respectively. These systems utilize advanced fluorescence sensing technology to provide accurate and stable glucose monitoring, allowing users to manage their diabetes effectively. Senseonics primarily generates revenue from markets outside the United States, highlighting its commitment to enhancing the lives of people with diabetes through long-term, differentiated glucose management solutions.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Heron Therapeutics is a biotechnology company dedicated to developing innovative treatments for unmet medical needs, primarily in the area of nausea and pain management. Utilizing its proprietary Biochronomer drug delivery technology, the company provides sustained therapeutic levels of short-acting pharmacological agents with a single administration over several days. Heron's product offerings include SUSTOL, an extended-release injection designed to prevent nausea and vomiting associated with certain chemotherapy regimens, and CINVANTI, an intravenous formulation for managing nausea linked to highly emetogenic chemotherapy. The company is also advancing investigational products such as HTX-011, a dual-acting combination of bupivacaine and meloxicam currently in Phase III trials for pain management, and HTX-034 for postoperative pain. Founded in 1983 and headquartered in San Diego, California, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

COMPASS Pathways plc is a mental health care company based in the United Kingdom and the United States, focusing on developing innovative therapies for treatment-resistant depression. The company is conducting Phase IIb clinical trials for its psilocybin formulation, COMP360, which aims to provide a new treatment option for patients who have not responded to conventional therapies. By researching psilocybin-assisted therapy, COMPASS Pathways seeks to assess its safety and efficacy, while combining the psychedelic compound with psychological support. The company was incorporated in 2020 and aims to address the significant unmet need for effective and accessible mental health treatments, striving to empower individuals facing mental health challenges.

Tipalti, Inc. is a company that specializes in accounts payable automation and global mass payments software. Founded in 2010 and headquartered in San Mateo, California, with an additional office in Kibbutz Glil-Yam, Israel, Tipalti's platform streamlines the payment process for businesses by automating various tasks such as invoice processing, supplier management, and payment reconciliation. The software supports features like tax compliance and global funds disbursement, allowing companies to efficiently manage payments to suppliers, partners, and affiliates. By implementing Tipalti's solution, organizations can reduce their supplier payment workload significantly, enabling them to focus on scaling their operations while maintaining compliance and improving financial controls. The company serves a diverse range of industries, including ad networks, ecommerce, online marketplaces, and video content providers.

Skydio, Inc. is a drone manufacturer based in Redwood City, California, founded in 2014. The company designs, assembles, and supports advanced drones that leverage artificial intelligence to enhance user experience. Skydio's drones are utilized in various sectors, including public safety, inspection, and defense, catering to consumers, enterprises, and government customers. Their products feature an array of cameras and proprietary computer vision technology that allows for real-time obstacle recognition and avoidance, enabling autonomous flight and intelligent decision-making. The company's initial offering was the R1 drone, which could autonomously track and film targets without human intervention. This was followed by the Skydio 2, which was more affordable and boasted improved tracking capabilities. The flagship model, the X2, is equipped with advanced features such as night vision and 100x zoom, allowing ordinary users to operate drones with ease. Skydio is supported by prominent investors and strategic partners, contributing to its growth in the competitive drone market.

AmplifyBio is a biotechnology company established in 2021 and headquartered in West Jefferson, Ohio. The company specializes in developing next-generation cell and gene therapies, with a focus on advancing human health through innovative treatment solutions. AmplifyBio's platform emphasizes research and development in areas such as vaccine technologies, bioanalytics, and drug development, aiming to accelerate the creation of therapies and vaccines. By leveraging cutting-edge technologies and novel research methodologies, AmplifyBio seeks to contribute to medical breakthroughs and improve access to effective treatments for a wide range of diseases.

Locus Robotics Corp. develops and manufactures autonomous mobile robots designed to enhance fulfillment operations in warehouses and e-commerce settings. Founded in 2014 and based in Wilmington, Massachusetts, the company offers LocusBots, which can handle various types of containers and integrate specialized peripherals to streamline order processing. These robots work collaboratively with human workers, significantly improving order productivity and increasing fulfillment speed and accuracy. This technology allows brands, retailers, and third-party logistics providers to efficiently manage high order volumes, meeting the demands of e-commerce and omnichannel retail. By reducing labor costs and adapting to fluctuating order volumes, Locus Robotics supports its clients in achieving effective and efficient warehouse operations.

Oak Street Health is a primary care center for adults on Medicare in medically-underserved communities where there is little to no quality healthcare. Its care is based on an entirely new model that is based on value for its patients, not on the volume of services. IT was founded in 2012 and headquartered in Chicago, Illinois.

At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.

Bright Machines, Inc. is a manufacturing company founded in 2018 and based in San Francisco, California, with additional offices in Tel Aviv, China, and Mexico. The company specializes in creating robotic arms and cells for micro factories, focusing on the assembly and inspection of electronic products. It aims to reduce manual labor in manufacturing by integrating advanced robotics with a software-defined manufacturing platform. This platform leverages artificial intelligence, machine learning, and production data to enhance automation processes, resulting in robots that are adaptable and equipped with sensor technology and computer vision. Bright Machines enables its clients to innovate rapidly and achieve better production yields at lower costs, meeting the evolving demands of the manufacturing sector.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in AI-powered software solutions that automate repetitive business tasks. The company's cloud-native platform integrates RPA with artificial intelligence, machine learning, and analytics to improve productivity, customer experience, and employee engagement. Key offerings include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server; and the Premier application for creating and managing automation visually. The company also provides solutions like Process inVision for documenting processes and various Testing Anywhere products for quality assurance across multiple platforms. Additionally, Automation Anywhere offers consulting services and has established a strategic partnership with Microsoft Azure. Founded in 2003 and headquartered in San Jose, California, the company operates offices in major global cities, including Boston, Dallas, New York, and various locations in Asia and Europe.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's product candidates include PRV-031, a monoclonal antibody currently in Phase III clinical trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor in Phase IIa trials for Crohn's disease. Additionally, PRV-3279 has completed Phase 1b trials for lupus, while PRV-101 is being developed as a vaccine for coxsackie virus B infections, which may prevent the onset of type 1 diabetes. Provention Bio also has a licensing agreement with Amgen for PRV-015, a monoclonal antibody targeting celiac disease. Founded in 2016 and based in Oldwick, New Jersey, Provention Bio aims to address the high morbidity and costs associated with chronic autoimmune and inflammatory diseases through its innovative predictive and preventive therapeutic approaches.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.

Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that develops therapeutics for cardiovascular, metabolic, and liver diseases. Its lead candidate, MGL-3196, is an orally administered, small-molecule, liver-directed thyroid hormone receptor (THR) ß-selective agonist currently in Phase III clinical trials for non-alcoholic steatohepatitis (NASH). This compound also targets familial hypercholesterolemia and demonstrates potential benefits in reducing triglycerides and improving metabolic conditions. Additionally, Madrigal is developing MGL-3745, another THR-ß-selective small molecule, which is in preclinical trials for NASH and hyperlipidemia. The company has a research and development agreement with Hoffmann-La Roche to collaborate on various licensed products. Founded in 2011, Madrigal Pharmaceuticals is headquartered in West Conshohocken, Pennsylvania.

Viridian Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with diseases that lack effective therapies. The company focuses on addressing conditions such as thyroid eye disease, a debilitating orphan disease characterized by inflammation and swelling of the eye muscles. One of its key product candidates, VRDN-001, is an insulin-like growth factor-1 receptor monoclonal antibody designed to potentially treat this condition. Viridian Therapeutics aims to provide new options for patients suffering from these underserved medical needs through its advanced research and development initiatives.

Carwow Ltd. operates an online platform that simplifies the car buying process for consumers by connecting them with dealerships. This platform allows users to compare offers on configured cars, facilitating a more efficient and cost-effective purchasing experience. In addition to connecting buyers with dealers, Carwow provides valuable resources such as car reviews, advice on selecting the right vehicle, information on financing options, and guidance on selling cars. Established in 2009 and based in London, the company was formerly known as Digital Blurb Limited and rebranded to Carwow in 2013. By improving transparency and eliminating the need for price haggling, Carwow enables consumers to find and purchase cars at reasonable prices while assisting dealers in increasing sales and enhancing stock turnover.

Esme Learning Solutions specializes in providing innovative online learning experiences tailored for executives, universities, and corporations. The company focuses on utilizing an artificial intelligence-based platform to enhance online education, helping educators deliver engaging and effective programs. Esme Learning offers personalized courses in areas such as blockchain, fintech, and digital engagement, enabling institutions to create impactful online learning opportunities for busy professionals. By integrating the latest business trends and technology, Esme Learning aims to empower individuals to advance their careers, launch new ventures, and enhance their business knowledge.

Lucira Health, Inc. is a medical technology company based in Emeryville, California, that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013, the company focuses on creating accessible and user-friendly testing solutions, including a disposable COVID-19 test kit designed for home use. This kit provides centralized-laboratory-accurate molecular testing in a compact format that operates on two AA batteries. It connects consumers to treatment options through a mobile application and offers a dual testing capability to determine whether viral respiratory symptoms are caused by COVID-19 or influenza. Lucira Health aims to enhance the accessibility and efficiency of infectious disease diagnostics.

TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.

Carwow Ltd. operates an online platform that simplifies the car buying process for consumers by connecting them with dealerships. This platform allows users to compare offers on configured cars, facilitating a more efficient and cost-effective purchasing experience. In addition to connecting buyers with dealers, Carwow provides valuable resources such as car reviews, advice on selecting the right vehicle, information on financing options, and guidance on selling cars. Established in 2009 and based in London, the company was formerly known as Digital Blurb Limited and rebranded to Carwow in 2013. By improving transparency and eliminating the need for price haggling, Carwow enables consumers to find and purchase cars at reasonable prices while assisting dealers in increasing sales and enhancing stock turnover.

Locus Biosciences is focused on developing a CRISPR-engineered platform aimed at transforming the treatment of bacterial diseases. This innovative platform integrates CRISPR-Cas3 technology with bacteriophage, which are viruses that specifically target and eliminate pathogenic bacteria. By leveraging this combination, Locus Biosciences enables healthcare providers to initiate treatment more rapidly, ultimately leading to improved medical outcomes for patients. The company's approach is designed to offer a precise and effective solution for addressing bacterial infections.

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.

3GTMS develops software that simplifies complex transportation management for shippers, brokers, and 3PLs. They have created a scalable TMS suite that manages the full transportation lifecycle from the rating, routing (including multi-stop and pool distribution optimization), tendering, tracking, tracing, and settlement in a single system.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Better Therapeutics is a company focused on the discovery, development, and commercialization of prescription digital therapeutics aimed at treating cardiovascular and metabolic diseases. It utilizes clinically validated, FDA-regulated software to promote behavior changes that address the underlying causes of these conditions, thereby enhancing quality of life, reducing reliance on medications, and lowering healthcare costs. The company's offerings include digital behavioral therapy that combines neuroscience, lifestyle medicine, and explainable artificial intelligence through a physician-prescribed mobile medical app. This approach leverages patient-generated data to guide clinical decision-making and optimize treatment outcomes. Better Therapeutics' current product pipeline features therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.

HiberCell, Inc. is a biotechnology company established in 2019 and located in New York. The company focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. HiberCell's therapeutic pipeline targets adaptive stress pathways and immune modulation to address the mechanisms of treatment resistance. By employing artificial intelligence and machine learning, the company integrates multi-omic and phenotypic profiles of tumors to generate insights that link these characteristics to clinical outcomes. This approach aims to enhance patient outcomes, enabling individuals to lead longer, cancer-free lives.

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections in the United States and internationally. Its lead product candidate, ibrexafungerp, is an innovative oral and intravenous treatment aimed at addressing various fungal infections, including vulvovaginal candidiasis and invasive candidiasis. The drug has successfully completed Phase 2 clinical trials for vulvovaginal candidiasis. Additionally, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials, antivirals, and oncology. The company also provides contract research services, such as medicinal chemistry and cGMP manufacturing, to pharmaceutical and life science partners. Founded in 1999 and originally known as SCYNEXIS Chemistry & Automation, Inc., the company changed its name in 2002 and is headquartered in Jersey City, New Jersey.

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics. The company offers a cloud database-as-a-service, known as SingleStore Managed Service, which enables analytics on the cloud of choice. Its flagship product, SingleStore DB, is a distributed SQL database that supports operational analytics on bare metal and hybrid cloud environments. SingleStore specializes in modernizing data platforms, securing government workloads, and facilitating IoT analytics, customer interactions, and risk management. It caters to a diverse range of industries, including financial services, media communications, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, the company has additional offices in Seattle, Boston, Portland, Lisbon, and London. Initially known as MemSQL Inc., it rebranded to SingleStore, Inc. in October 2020.

CloudBolt provides solutions to help enterprises manage and govern their hybrid cloud and optimize their automation strategy. With CloudBolt, companies can configure and manage private and public cloud resources—quickly, securely, and cost-effectively—while empowering DevOps and end-users with self-service provisioning environments. Today, CloudBolt is deployed in the world’s largest enterprises, across all industries, including financial services, government, healthcare, manufacturing, retail, technology services, and more.

Udacity is an online learning platform founded in 2011 by David Stavens, Mike Sokolsky, and Sebastian Thrun, headquartered in Mountain View, California. Originating from free computer science courses at Stanford University, Udacity focuses on providing vocational training in high-demand fields such as artificial intelligence, machine learning, data science, and cloud computing. The platform offers various nanodegree programs, including web development, data analysis, and mobile app development, designed to equip learners with skills sought by employers. Udacity's mission is to democratize education, making it accessible and affordable for individuals aiming to enhance their career prospects. The company collaborates with technology firms to ensure its curriculum aligns with industry needs, thereby preparing learners for the evolving job market. Despite facing challenges in its early years, Udacity has grown significantly, boasting millions of users and a valuation exceeding $1 billion, supported by investments from prominent venture capital firms.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics. The company offers a cloud database-as-a-service, known as SingleStore Managed Service, which enables analytics on the cloud of choice. Its flagship product, SingleStore DB, is a distributed SQL database that supports operational analytics on bare metal and hybrid cloud environments. SingleStore specializes in modernizing data platforms, securing government workloads, and facilitating IoT analytics, customer interactions, and risk management. It caters to a diverse range of industries, including financial services, media communications, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, the company has additional offices in Seattle, Boston, Portland, Lisbon, and London. Initially known as MemSQL Inc., it rebranded to SingleStore, Inc. in October 2020.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats. Utilizing a cloud-based platform, ZeroFox offers real-time analytics and protection against various cyber threats, including phishing attacks, account takeovers, and impersonation. The company's services include proactive monitoring of social media and digital communication platforms to identify and mitigate risks, safeguarding both brands and high-value individuals like executives from targeted fraud and scams. ZeroFox also provides specific solutions for political campaigns to defend against election-related threats. With a focus on comprehensive threat intelligence, the company employs advanced technology to monitor the surface, deep, and dark web, ensuring businesses can respond effectively to emerging threats. Founded in 2013 and headquartered in Baltimore, Maryland, ZeroFox has additional offices in London, Chile, and India, serving clients across diverse sectors such as finance, healthcare, and education.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.

Dashlane Inc. is a software developer specializing in password management and secure digital wallets. Founded in 2009 and headquartered in New York, with additional offices in Paris and Lisbon, Dashlane offers a comprehensive password manager that imports passwords from various browsers into a secure vault. Its solutions include Autofill for online forms, a Digital Wallet for tracking receipts, and security tools for both individual users and businesses. The company’s offerings, such as Dashlane Business 2.0, help improve password security and reduce the risks associated with unsecure password sharing. With over 19 million users and 22,000 businesses globally, Dashlane aims to simplify the management of digital identities, allowing users to securely store and change passwords, automatically log in, and make payments without manual entry.

Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing innovative medicines aimed at improving the lives of patients suffering from immune-mediated diseases. The company's lead investigational drug, reproxalap, is a first-in-class treatment that is in late-stage development for dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing other product candidates for a range of conditions, including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, autoimmune diseases, and certain cancers. The company's efforts are dedicated to addressing unmet medical needs through the development of next-generation therapies.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

FuelCell Energy, Inc. is a company that designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants, focusing on distributed power generation and hydrogen production. The company offers a range of solutions, including its SureSource product line, which employs carbonate fuel cell technology for on-site power generation, utility grid support, and hydrogen production. Additionally, FuelCell Energy provides systems for carbon dioxide capture from flue gases and energy storage solutions based on solid oxide technology. The company's products are utilized across various sectors, including utilities, industrial applications, healthcare, data centers, and government facilities. FuelCell Energy operates primarily in the United States, with a presence in South Korea, England, and Germany. Founded in 1969 and headquartered in Danbury, Connecticut, the company is committed to delivering ultra-clean energy solutions that support decarbonization and net-zero commitments.

TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for urologic conditions in the United States. The company's primary product candidate, vibegron, is an oral small molecule beta-3 agonist aimed at treating overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain associated with irritable bowel syndrome. Additionally, Urovant is investigating URO-902, a gene therapy designed for patients with OAB who have not responded to oral pharmacological treatments. Founded in 2016 and based in London, Urovant Sciences operates as a subsidiary of Sumitovant Biopharma Ltd.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines aimed at treating complex diseases that are resistant to conventional therapies. Utilizing its proprietary Mesenchymal Precursor Cell (MPC) technology, the company targets a range of conditions, including cardiovascular disorders, orthopedic spine issues, inflammatory diseases, and various cancers. Key products in development include MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain. Additionally, Mesoblast is advancing MPC-300-IV, currently in Phase II trials, for the treatment of biologic refractory rheumatoid arthritis and diabetic kidney diseases. The company operates in several countries, including the United States, Australia, and the United Kingdom, and has established strategic partnerships to enhance its product offerings in specific markets. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast is committed to leveraging its innovative technology to address unmet medical needs.

Contentful is a content management system that empowers businesses to create and manage digital experiences across various channels. Serving 30% of the Fortune 500 and numerous global brands, the platform allows for greater speed and scalability compared to traditional content management systems. It centralizes and structures content within a single hub, enabling easy reuse across multiple digital properties. Contentful also offers extensive integration capabilities with hundreds of other tools through open APIs, making it a flexible solution for organizations. Prominent clients, including Chanel, Bang & Olufsen, Shiseido, Shopify, and BP, utilize Contentful to enhance their digital strategies.

Acacia Pharma Ltd. is a pharmaceutical company based in Cambridge, United Kingdom, dedicated to discovering and developing supportive care drugs primarily for cancer patients. The company’s product portfolio features APD405, an injectable formulation aimed at treating nausea and vomiting, APD209 for cancer cachexia, and APD421, an intravenous formulation for preventing and treating nausea and vomiting. Acacia Pharma also focuses on addressing cancer-related issues such as fatigue and xerostomia. Incorporated in 2006, Acacia Pharma aims to enhance the quality of care for patients undergoing medical treatments, including surgery and chemotherapy.

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. The firm aims to improve the surgical experience for both surgeons and patients by integrating advanced technologies such as augmented intelligence, connectivity, and robotics into the surgical process. Its flagship product, the Senhance Surgical System, represents the first machine vision system designed for robotic surgery, enhanced by the Intelligent Surgical Unit that facilitates augmented intelligence. By addressing existing clinical, cognitive, and economic challenges within the surgical field, Asensus Surgical seeks to transform surgical practices and improve outcomes for patients globally.

CloudPay is a provider of managed global payroll services, offering a unified cloud-based platform designed for multinational organizations. Its solution delivers end-to-end payroll management, ensuring consistent and compliant payroll processing across over 130 countries in more than twenty-five languages. By standardizing payroll functions, CloudPay helps organizations enhance efficiency, streamline compliance, and gain better visibility into payroll performance and costs. The company leverages over twenty years of industry experience and has successfully served more than 2,500 multinational entities. CloudPay has been recognized for its innovative technology and service, receiving multiple awards, including accolades for Global Payroll Transformation and Payroll Software Product of the Year.

RumbleOn is an online retailer based in the United States that facilitates the buying, selling, trading, and financing of pre-owned motorcycles for both consumers and dealers. The company primarily focuses on Harley-Davidson motorcycles and operates within the broader powersports and automotive sectors. Its main revenue comes from the distribution of motorcycles and other powersports vehicles, while it also engages in the distribution of cars and trucks. In addition to vehicle sales, RumbleOn provides nationwide logistics and transportation services, enhancing the efficiency and transparency of the retail experience for its customers.

Dashlane Inc. is a software developer specializing in password management and secure digital wallets. Founded in 2009 and headquartered in New York, with additional offices in Paris and Lisbon, Dashlane offers a comprehensive password manager that imports passwords from various browsers into a secure vault. Its solutions include Autofill for online forms, a Digital Wallet for tracking receipts, and security tools for both individual users and businesses. The company’s offerings, such as Dashlane Business 2.0, help improve password security and reduce the risks associated with unsecure password sharing. With over 19 million users and 22,000 businesses globally, Dashlane aims to simplify the management of digital identities, allowing users to securely store and change passwords, automatically log in, and make payments without manual entry.

Metalysis Limited is a technology company based in Rotherham, United Kingdom, specializing in the manufacture of high-value metals and alloys, including titanium and tantalum. Founded in 2001, the company employs a solid-state process developed from research at the University of Cambridge to produce metal alloy powders that are primarily utilized in advanced manufacturing sectors such as aerospace and automotive. This innovative method is designed to be more environmentally friendly and energy-efficient compared to traditional melting technologies. Metalysis also provides powder metallurgy, additives, and analytical services, and has established commercial partnerships with various industry and academic entities. The company's Generation 4 technological expansion aims to scale production to industrial levels, further enhancing its capabilities in delivering 3D printable metal powders for diverse applications.

Gibraltar Business Capital (GBC) provides small- to medium-sized business owners fresh and accessible capital alternatives to a commercial bank loan, which is typically more restrictive. With fast, flexible asset based lending and factoring solutions, we act as a bridge to financial stability, delivering lines of credit and specialized small business funding in a highly reliable and always accommodating environment. Our perspective is that there is no one-size-fits-all solution. We look holistically first at the specific issues, history and people involved in a business and tailor capital solutions to fit, not the other way around. We work directly with business owners and their advisors to secure rapid, creative capital when companies need it most—and need it to grow. Meeting a strong demand in today’s shifting marketplace—when even once bankable customers may be faced with a net operating loss, financing before, during and after bankruptcy, or some other financial predicament—our resourceful, professional lending team delivers clear, quick and independent working capital to get businesses back on track. While our corporate office is located in the north suburbs of Chicago, IL, we have sales representation throughout the entire US. Visit our website at www.gibraltarbusinesscapital.com to find a sales representative in your area or contact our corporate office at 847-272-9618 to learn more about how we can help finance your business today.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, dedicated to the development and commercialization of its lead drug candidate, TRC101. This non-absorbed, orally-administered polymer is designed to treat metabolic acidosis, a condition often associated with chronic kidney disease (CKD). Metabolic acidosis can contribute to the progression of CKD and is linked to various health issues such as muscle wasting, loss of bone density, and increased mortality risk. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, aiming to provide an effective treatment option for patients suffering from this condition. The company was founded in 2013 and is focused on addressing the unmet medical needs of individuals with CKD.

Medsphere Systems Corporation provides open source software for the healthcare industry. It offers OpenVista, a portfolio of products and professional services for hospitals, clinics, and integrated delivery networks. The company's OpenVista includes OpenVista Enterprise, an electronic health record solution that offers patient and health information management system, clinical information system, laboratory, pharmacy, radiology, nutrition and food service, and interface suite modules. In addition, the company offers implementation, training, support, and development services. Medsphere Systems Corporation was founded in 2002 and is headquartered in Carlsbad, California.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.